Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

nd the timing of any such approvals, including whether a clinically meaningful response improvement can serve as the basis for accelerated approval of FavId and whether it will receive expedited review as a result of the Fast Track designation; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of FavId for use in clinical trials and, if FavId receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using FavId; potential delays in patient enrollment; Favrille's ability to obtain additional financing to support its operations, including the conditions to the Company's ability to access the committed equity financing facility and therefore fund operations through the first half of 2008; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

FAVRILLE, INC.

(a development stage company)

BALANCE SHEETS

(in thousands, except share and per share data)

September December


'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Calif. , Sept. 16, 2014  ROX ... trial, an international multi-center, prospective, randomized, controlled, blinded ... treatment of arterial hypertension. The CONTROL-HTN trial, NCT01642498, evaluated ... creating a fixed connection between a central artery ... the treatment of hypertension. The primary outcomes are ...
(Date:9/16/2014)... 2014 The Pulmonary Fibrosis Foundation (PFF) announced ... than 1,100 patients and families suffering from pulmonary fibrosis ... for the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary ... initiative to seek patient input in order to better ... "We applaud the FDA for focusing its attention ...
(Date:9/16/2014)... 16, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... commencing an underwritten registered public offering of shares ... are being offered by Aratana Therapeutics. ... joint book-running managers for the offering.  ...
Breaking Medicine Technology:ROX Medical presents positive data for CONTROL-HTN resistant hypertension trial 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4Aratana Therapeutics, Inc. Announces Proposed Public Offering 2
... WASHINGTON, March 3, 2011 The Generic Pharmaceutical ... drug manufacturers and suppliers, has honored Pharmaceutical ... Merritt with the industry,s prestigious "Outstanding Contribution" ... ) The award was presented at ...
... We are pleased to announce the launch of ... database of contract laboratory outsourcing and regulatory opportunities. ... vendors to fulfill your contract laboratory testing and ... regulatory outsourcing assignments. You also can post free for a ...
Cached Medicine Technology:Generic Drug Industry Honors PCMA President & CEO Mark Merritt with Prestigious 'Outstanding Contribution' Award 2Announcing New Contract Laboratory Testing and Outsourcing Web Database 2
(Date:9/17/2014)... 2014 In honor of National Health ... to health IT professionals for gaining a competitive edge ... by HIMSS shows demand for qualified health IT professionals ... set is the differentiating factor when filling a position. ... professional that has clinical workflow and terminology experience. American ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Lee Berman, ... industry, will be appearing on The Balancing Act® airing ... September episodes. , The segment will premiere on September ... 'The Balancing Act® airing on Lifetime Television®' with show ... Asset Funding Corp. for over a decade and is ...
(Date:9/17/2014)... On October 1-2, Voom will be adding ... Techmanity, a celebration of the intersection of life and ... Techmanity will host the best and brightest across the ... of Cisco, PayPal, Samsung, Silicon Valley Bank, and Adobe ... , Voom was created to address the health concerns ...
(Date:9/17/2014)... Health.Verticalize, a healthcare marketing company which helped ... options in the 2014 open enrollment period, has announced ... Health Network will be using HealthNetwork.com ... remained out of the spotlight for the last twelve ... to its present position with dozens of targeted sites ...
(Date:9/17/2014)... Presence Technology, a multinational provider ... Suite 10.0, which incorporates significant enhancements to meet ... , The Contact Center Agents and Supervisors will ... get a better feel for the performance of ... and who requires additional coaching or mentoring to ...
Breaking Medicine News(10 mins):Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 2Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 3Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 4Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2Health News:Health and Wellness Startup Voom Announces Sponsorship at Techmanity 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 3Health News:Presence Technology’s 10.0 Release Drives Contact Center Web Supervisor Effectiveness While Reducing Operation Costs and Delivering Enterprise Grade Scalability 2
... moxifloxacin cut recovery time by 2 months, researchers say ... antibiotic moxifloxacin to the standard combination of drugs used ... the time needed to cure patients from six months ... study of more than 170 people in Rio de ...
... George Abercrombie, president,and chief executive officer, Hoffmann-La Roche ... at The Economic Club of Memphis that the,threat ... unlike those,anticipated with traditional emergency preparedness plans. ... for potential,disasters such as floods or tornadoes," according ...
... -- A single dose of Otsukas investigational oral ... favorable changes in hemodynamics associated with a significant ... heart failure (ADHF) who participated in the international ... in Subjects with HEart failure (ECLIPSE), presented at ...
... A Florida pharmacy,owner and a Kentucky physician pleaded ... pharmacy business that generated more than,$126 million in ... Assistant Attorney General Alice S. Fisher of the ... the Southern District of,California announced today. Claude ...
... 2008, RANCHO MIRAGE, Calif., Sept. 19 The,International ... first,annual Gala, "The South American Extravaganza" February 8, 2008. ... The elegant black-tie dinner will be held at the ... at 6:00 pm with cocktails. At,7:00 pm, a dinner ...
... Calif., Sept. 19 Over 800 patients ... survey conducted by the Renal,Support Network, a ... that affect the care of patients with ... education, reimbursement for,transplant medications and dialysis services. ...
Cached Medicine News:Health News:Newer Antibiotic Speeds TB Healing 2Health News:CEO Addresses Tennessee Business Leaders About Developing Pandemic and Business Continuity Plans 2Health News:CEO Addresses Tennessee Business Leaders About Developing Pandemic and Business Continuity Plans 3Health News:ECLIPSE data on effects of Otsuka's investigational novel treatment, Tolvaptan 2Health News:Doctor and Pharmacy Owner Plead Guilty in Internet Pharmacy Conspiracy 2Health News:Doctor and Pharmacy Owner Plead Guilty in Internet Pharmacy Conspiracy 3Health News:IMA South American Extravaganza Dinner to Honor Coachella Valley Doctor 2Health News:New Survey Reveals Kidney Patients' Concern About Medicare Policies 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: